Gastrointestinal bleeding (GIB) remains a common yet challenging clinical scenario, with substantial morbidity and mortality. It necessitates a multidisciplinary approach for optimal management, involving gastroenterologists, surgeons, radiologists, and intensivists.
Understanding the pathophysiology of GIB is essential for effective clinical management. The bleeding source could be upper (esophageal, gastric, or duodenal) or lower (jejunum, ileum, colon, rectum, or anus). Clinical presentation varies from asymptomatic occult bleeding to life-threatening hemorrhage, often manifesting as melena, hematochezia, or hematemesis.
Endoscopy remains the gold standard for diagnosing GIB, offering therapeutic interventions simultaneously. However, the timing of endoscopy depends on the patient's hemodynamic status and the bleeding severity. Other modalities include radiological investigations like CT angiography for ongoing active bleeding and capsule endoscopy or balloon-assisted enteroscopy for obscure GIB.
Initial management focuses on hemodynamic stabilization with fluid resuscitation and blood transfusion, if necessary. Proton pump inhibitors are recommended for suspected upper GIB. Endoscopic therapy, including injection, thermal coagulation, or mechanical methods, is the cornerstone for definitive treatment. For refractory cases, interventional radiology or surgery may be required.
Several scoring systems like the Glasgow-Blatchford Score or the Rockall Score can help predict rebleeding and mortality, assisting in risk stratification and management planning. Comorbidities, age, and the severity of the initial bleed also impact prognosis.
Managing GIB in clinical practice requires a comprehensive, multidisciplinary approach. Accurate diagnosis, prompt management, and appropriate risk stratification are key to improving patient outcomes. Further research is needed to refine management strategies and improve prognostication tools.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation